SeeThruEquity Issues Update on M Pharmaceutical, Inc. (CSE: MQ; OTCQB: MPHMF)

NEW YORK, NY / ACCESSWIRE / September 15, 2015 / SeeThruEquity, a leading independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced it has issued an update on M Pharmaceutical, Inc. (CSE: MQ; OTCQB: MPHMF).

The report is available here: MQ Update Note. SeeThruEquity is an approved equity research contributor on Thomson First Call, Capital IQ, FactSet, and Zack’s. The report will be available on these platforms. The firm also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

Headquartered in Vancouver, BC, M Pharmaceutical (“M Pharma,” CSE: MQ, OTCQB: MPHMF, FWB:T3F2), is a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The Company acquired the exclusive rights to three technologies invented by Dr. Martin Mintchev at the University of Calgary: (1) Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; (2) Trimtec, gastrointestinal neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach; and (3) eMosquito wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics.

M Pharma has had several notable developments since our initiation report on the company in June, with highlights as follows.

New CEO to lead clinical and commercial development

On September 1, 2015, Matthew B. Lehman became President and Chief Executive Officer of M Pharma. Lehman assumes the role from Dr. Martin Mintchev, M Pharma’s co-founder and lead inventor Lehman has over 15 years of executive level experience in the development of therapeutics, including serving as CEO of Prima Biomed, Ltd., a dual listed public company developing cancer immunotherapies. At Prima Biomed Ltd., Lehman served as CEO through critical stages of clinical development of the company’s lead product at the time, obtaining both fast track and orphan drug designations from FDA. Lehman will be based in Cincinnati, OH, and will seek to establish M Pharma’s US operating presence. Dr. Mintchev has been appointed Chief Scientific Officer. The addition of Lehman as CEO is a continuation of an expanding leadership and advisory team at M Pharma. On July 17, 2015, the company added esteemed University of Calgary gastrointestinal surgeon and diabetes researcher Dr. Oliver Frank Bathe, MD, MSc, FRCS(C), FACS, to its Advisory Board.

New CEO has delivered clarity on the company development plans

In a recent letter to shareholders, Lehman outlined general plans for development of M Pharma’s technologies. We are encouraged by the clear milestones and value creation catalysts forthcoming from the company.

Manufacturing agreement in place for Trimtec

On August 17, 2015, M Pharma announced that it had engaged Changzhou, China-based Rishena Co., Ltd., to manufacture Trimtecgastrointestinal functional neurostimulators. Under the terms of the manufacturing supply agreement, Rishena will be the exclusive supplier of laparoscopically-implantable Trimtec devices to M Pharma for markets in North America and South America. The devices will be fully programmable and rechargeable through an abdominal belt, and Rishena has indicated that it will obtain ISO 13485 certification for Trimtec manufacturing, at its expense, prior to M Pharma’s commercial launch of Trimtec. M Pharma plans to market Trimtec as a medical device in the US. M Pharma is initially contemplating an FDA 510(k) application based on EnteroMedics’ predicate device, the Maestro(R) Rechargeable System, delivering vBloc(R) Neurometabolic Therapy, which was FDA approved in 2014.

Maintain price target of CAD $0.79

We are maintaining our price target of CAD $0.79 (USD $0.60) per share for M Pharma at this time. If achieved, the prIce target would represent potential upside of 618% from the recent price of CAD $0.11. We view M Pharma as an intriguing high risk / high reward investment targeting a large and growing segment of the healthcare industry.

Please review important disclosures on our website at www.seethruequity.com.

About M Pharmaceutical, Inc.

Formed in early 2015, M Pharmaceutical Inc. is a clinical-stage company developing innovative technologies for the monitoring and treatment of obesity, diabetes, and other gastroenterological indications. The Company acquired the exclusive rights to three technologies invented by Dr. Martin Mintchev at the University of Calgary: (1) Trimeo capsules, temporary controllable pseudobezoars for non-invasive gastric volume reduction for the treatment of obesity; (2) Trimtec, gastrointestinal neurostimulators implanted laparoscopically for the treatment of obesity and gastroparesis without permanent anatomical modification of the stomach; and (3) eMosquito wearable blood monitor, for automatic and autonomous monitoring of blood glucose by diabetics.

About SeeThruEquity

SeeThruEquity is an equity research and corporate access firm focused on companies with less than $1 billion in market capitalization. The research is not paid for andis unbiased. The company does not conduct any investment banking or commission based business. SeeThruEquity is approved to contribute its research to Thomson One Analytics (First Call), Capital IQ, FactSet, Zacks, and distribute its research to its database of opt-in investors. The company also contributes its estimates to Thomson Estimates, the leading estimates platform on Wall Street.

For more information visit www.seethruequity.com.

Contact:

Ajay Tandon
SeeThruEquity
info@seethruequity.com

SOURCE: SeeThruEquity

ReleaseID: 431978